Tarsus Pharmaceuticals, Inc. Common Stock
TARSTarsus Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for eye diseases, particularly those with high unmet medical needs. The company emphasizes the development of targeted treatments for conditions such as Demodex blepharitis, aiming to improve patient outcomes through novel pharmaceutical solutions.
Company News
Tarsus Pharmaceuticals will host a live webcast on November 4, 2025, to report its third quarter 2025 financial results and provide a corporate update. The company has FDA-approved XDEMVY for Demodex blepharitis and is developing additional treatments for eye care and infectious disease prevention.
Capricorn Fund Managers Ltd acquired 484,500 shares of Phreesia, valued at $11.4 million, representing 3.8% of their reportable assets under management. The investment comes as Phreesia reaches a milestone of first quarterly net income and plans to expand payment solutions.
Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.
Elanco Animal Health has sold certain future royalties and commercial milestones associated with its Xdemvy product to Blackstone for $295 million. The company will use the proceeds to reduce its debt and expects to achieve a net leverage ratio of 3.9x-4.3x EBITDA by the end of 2025.
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
